| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10968514 | Vaccine | 2013 | 6 Pages |
Abstract
⺠A new 5-valent rotavirus vaccine has been evaluated in a double-blind phase 1 trial. ⺠No severe adverse events were observed. ⺠There was no significant difference in the frequency of AE between vaccine and control groups. ⺠The proportion of seroconversion was larger in the vaccine group for all five serotypes. ⺠Antibody levels were significantly higher in the vaccine group in comparison to the placebo group.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Expedito J.A. Luna, Neuza M. Frazatti-Gallina, Maria C.S.T. Timenetsky, Maria R.A. Cardoso, Maria A.S.M. Veras, João L. Miraglia, Ana M.U. Escobar, Sandra J.F.E. Grisi, Isaias Raw, Alexander R. Precioso,